IL2 and amyotrophic lateral sclerosis: To this end, a randomized, placebo-controlled, double-blind phase-II clinical trial, MIROCALS (NCT03039673), is currently active and aims to evaluate the effect of 2MIU-IL-2 in a larger ALS cohort of 220 participants.